AlphaQuest LLC Boosts Stake in Pfizer Inc. $PFE

AlphaQuest LLC increased its position in Pfizer Inc. (NYSE:PFE) by 196.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 60,523 shares of the biopharmaceutical company’s stock after purchasing an additional 40,118 shares during the quarter. AlphaQuest LLC’s holdings in Pfizer were worth $1,542,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Argent Advisors Inc. raised its holdings in Pfizer by 5.1% in the third quarter. Argent Advisors Inc. now owns 109,337 shares of the biopharmaceutical company’s stock worth $2,786,000 after purchasing an additional 5,318 shares in the last quarter. Everett Harris & Co. CA increased its stake in shares of Pfizer by 0.4% in the 3rd quarter. Everett Harris & Co. CA now owns 268,380 shares of the biopharmaceutical company’s stock worth $6,838,000 after acquiring an additional 1,148 shares in the last quarter. Cahill Financial Advisors Inc. increased its stake in shares of Pfizer by 2.4% in the 3rd quarter. Cahill Financial Advisors Inc. now owns 22,284 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 517 shares in the last quarter. Impact Partnership Wealth LLC bought a new stake in Pfizer during the third quarter worth about $611,000. Finally, Cypress Capital Group grew its holdings in Pfizer by 851.0% in the third quarter. Cypress Capital Group now owns 114,220 shares of the biopharmaceutical company’s stock worth $2,910,000 after purchasing an additional 102,210 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Zacks Research lowered shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Cantor Fitzgerald lifted their price objective on Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a research note on Tuesday. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Citigroup began coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Finally, HSBC reissued a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.43 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market cap of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47. The business has a 50-day simple moving average of $25.52 and a two-hundred day simple moving average of $25.03. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post‑COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi‑year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
• Positive Sentiment: Pfizer struck a non‑exclusive licensing agreement to access Novavax’s Matrix‑M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full‑year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near‑term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near‑term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short‑term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.